# Evaluating the Efficacy of Retatrutide in Obesity and Cardiovascular Disease

Canonical source: https://retacompare.com/research/evaluating-the-efficacy-of-retatrutide-in-obesity-and-cardiovascular-disease

Clinical Trials · 2025-07-23


    This study aims to assess the efficacy and safety of retatrutide in individuals with obesity and cardiovascular disease. Conducted over approximately 113 weeks, the research focuses on understanding how retatrutide, administered weekly, impacts this specific population.

 What this source covers

The source details a clinical trial (NCT05882045) designed to evaluate retatrutide (LY3437943) in participants diagnosed with obesity and established cardiovascular disease (CVD). The primary objectives include measuring the drug's efficacy and safety profile over the trial duration.

 Why it matters for Retatrutide research

This research is significant as it explores the dual challenges of obesity and cardiovascular disease, conditions that often coexist and complicate treatment strategies. Understanding the effects of retatrutide in this context may provide insights into its potential as a therapeutic option for patients facing these health issues.

 Key findings or claims

The study evaluates the efficacy of retatrutide in participants with obesity and CVD.

It focuses on both the safety and efficacy of the drug.

The trial duration is approximately 113 weeks.

Participants will receive retatrutide once weekly.

The study aims to provide data relevant to managing obesity in patients with cardiovascular conditions.

 Context and prior work

Retatrutide is part of a growing class of medications that target multiple pathways involved in metabolic regulation, including GLP-1, GIP, and glucagon receptors. Previous studies have indicated that GLP-1 receptor agonists can lead to weight loss and improved cardiovascular outcomes. By investigating retatrutide in a population with both obesity and CVD, this trial contributes to the broader understanding of how these agents can be used in clinical practice.

 Practical takeaways for researchers

Researchers should consider the implications of this trial for future studies on retatrutide and similar agents. The focus on a population with both obesity and cardiovascular disease highlights the need for targeted therapies that address multiple health issues simultaneously. Furthermore, the results may influence treatment guidelines and patient management strategies in clinical settings.

 FAQ

 What is the primary goal of the study?

The primary goal is to evaluate the efficacy and safety of retatrutide in participants with obesity and cardiovascular disease.

 How long will the study last?

The study is expected to last about 113 weeks.

 How is retatrutide administered in the trial?

Retatrutide is administered once weekly to participants in the trial.

 Source: ClinicalTrials.gov · NCT05882045 · published 2025-07-23.

## Sources

- ClinicalTrials.gov · NCT05882045: https://clinicaltrials.gov/study/NCT05882045